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HYPERGLYCEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANT (ALLOHSCT)PATIENTS: PREVALANCE AND IMPACT ON OUT-
COMES
Zimmerman, R.L., Labrezio, F.R., Devetten,M.P., Goldner,W. Univer-
sity of Nebraska Medical Center, Omaha, NE
Background: Immunosuppressive medications such as tacroli-
mus, sirolimus, and corticosteroids are known to cause insulin resis-
tance in solid organ transplant patients (pts). Pts receiving alloHSCT
are often on immunosuppressants and develop some degree of
hyperglycemia. Diabetes and hyperglycemia are associated with
complications such as renal disease, cardiovascular disease, an
increase in inflammatory processes, and increased risk of infections.
We reported the prevalence of hyperglycemia in the first 100 days
following alloHSCT as well as average blood sugar values and the
association between blood sugars, length of stay, renal, pulmonary,
and infectious complications.
Methods:Beginning Feb, 2007, blood sugars on all alloHSCTpts
were monitored for 100 days. Inpts were treated with IV or subcuta-
neous insulin as appropriate for a goal blood sugar\140 ng/dl. ADA
guidelines for diagnosing diabetes (two fasting blood sugars of$126
on separate occasions, or one random blood sugar of $200) were
used to diagnose hyperglycemia in the outpatients. Outpts were
referred to Endocrine (in a timely manner) within 2 days and the
diabetic educators who counseled the pts and family on diet, insulin
therapy, and blood sugar monitoring.
Results: 32 pts received alloHSCT during the study period.
Seventeen pts (53%) required treatment for hyperglycemia. Theme-
dian (range) glucose level was 150 (109–189) in pts who received
treatment while those who did not receive hyperglycemia treatment
was 108 (92–132; (p\ 0.001) In pts who received treatment, 24%
had a prior history of diabetesmellitus,82%were on systemic steroids
vs 40%of the non-treatment group (p5 0.01), and 41%were on total
parenteral nutrition vs none in the non-treatment group (p5 0.005).
The treatment group had a higher rate of acute GVHD, 65% vs 27%
in the non-treatment group (p 5 0.03), while 82% developed some
type of infection versus 20% in the non-treatment group (p 5
\0.001). 18% of the treatment group died within 100 days, while
no deaths occurred in the non-treatment group.
Conclusions: AlloHSCT pts that develop hyperglycemia have
higher rates of infection andGVHD. Pts who developed hyperglyce-
mia also had higher rates of steroid and TPN usage, indicating these
are potential risk factors for the development of hyperglycemia and
merit aggressivemonitoring of blood glucose. Further studies should
evaluate if early hyperglycemia recognition and treatment decrease
the incidence of complications.310
INCREASED MUCOSITIS IN PATIENTS RECEIVING TARGETED VS NON-
TARGETED IV BUSULFAN PRIOR TO ALLOGENEIC STEM CELL TRANS-
PLANTATION
Nimmagadda, S., Sweiss, K., Chunduri, S., Beri, R., Peace, D.J.,
Quigley, J., Dobogai, L., Mahmud, N., Rondelli, D. Section Hematolo-
gy/Oncology, University of Illinois At Chicago, Chicago, IL
In this study we retrospectively analyzed the results of allogeneic
hematopoietic stem cell transplantation (HSCT) in 47 patients who
received a conditioning regimen with fludarabine and myeloablative
doses of intravenous (IV) busulfan (BU). Patients were divided in
two groups: the first (n 5 21) received a fixed dose of IV BU at 3.2
mg/kg in a single dose/day x 4 days; the secondgroup (n5 26) received
targeted doses of IV BU (target AUC: 4800 mM*min) in four single
daily injections. Targeted doses of BU were calculated mostly based
on a pre-transplant test dose, or in some patients based on pharmaco-
kinetics studies done after the first dose of BUduring the conditioning
regimen.Themeandaily dose ofBUadministered in the secondgroup
was 3.4 6 0.6 mg/kg. No significant differences between the two
groups were detected analyzing the characteristics of the patients,
such as age, high risk disease, related vs non-related donor, or
CD341 cell dose. Median time to absolute neutrophil count (ANC)
$ 0.5  109/L was 18 days (range: 11–35) in the group that received
non-targeted BU and 15 days (range: 10–22) (p 5 ns) in the group
that received targeted-BU, whereas median time to platelets $ 20 
109/L was 13 days (range: 0–37) and 15 days (range: 0–49) (p 5 ns),
respectively. Post-transplant mucositis was graded according to theWHO criteria and 73% of the patients who received targeted-BU
experienced a grade 3–4mucositis as compared to 35%of the patients
who received a fixed dose of BU. No differences in other extra-hema-
tologic toxicities were observed, and particularly none of the patients
had venous-occlusive disease (VOD). These findings suggest that the
use of targeted-IV BU results, on average, in the administration of
a higher BU dose compared to the standard 3.2 mg/kg and this could
explain the increased rate of severe mucositis after allogeneic HSCT.
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CONDITIONING WITH NON-TARGETED BUSULFAN AND FLUDARABINE
FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION: A STUDY
OF ENGRAFTMENT KINETICS
Nathan, S., Tuncer, H., Maciejewski, J., Venugopal, P., Larson, M.,
Shammo, J., Gregory, S., Fung, H. Rush University Medical Center, Chi-
cago, IL
Introduction: Busulfan/ Fludarabine (BuFlu) combination che-
motherapy is increasingly being used in reduced intensity allogeneic
transplantation. Targeted Bu has been used by some transplant cen-
ters, however, its impact on engraftment kinetics and outcome are
not clear. Here, we report our experience with using a non-targeted
Bu and Flu conditioning regimen for allogeneic stem cell transplan-
tation (AlloSCT).
Methods:Data from 24 consecutive patients (pts), undergoingAl-
loSCT using the BuFlu conditioning regimen [Bu (130mg/m2 IV
daily) and Flu (40mg/m2 daily) x 4 days], treated at our institution,
were collected. Demographics, indication, time to engraftment
(TE), chimeric status at Day (D)100 post-transplant, tolerability
and outcomes were analyzed.
Results: 24 pts (average age 49.95 yrs, range: 26–68yrs) were iden-
tified and analyzed as a retrospective cohort with a follow-up duration
of 208.46 182.5D (Range 21–663D). 12 (50%) pts weremale and 12
(50%) female. 79.2% were Caucasian. 13 (54.2%) pts had$2 comor-
bidities. Indications included de novo or secondary acute myeloge-
nous leukemia, chronic myelogenous leukemia or aplastic anemia,
myelodysplastic syndrome or myeloproliferative disease that failed
prior therapy. 12 (50%) pts (age - 51.836 9.1 yrs) underwentmatched
related donor (MRD) and 12(50%) pts (age – 48.16 12.8 yrs)matched
unrelated donor (MUD) AlloSCT. Time to engraftment was 16.5 6
4.63 D in the MRD pts and 15.54 6 3.3 D in the MUD pts. BuFlu-
related toxicities included mucositis, infections, organ-dysfunction
and graft versus host disease. Chimerism studies were not available
in 5 pts. At D100 post-AlloSCT,11 (57.9%) pts. had complete chime-
rism (CC) with .99% donor cells (DC) of who 7 (63.7%) stayed in
remission (CR), 3 (27.3%) died from transplant related toxicities
(TRT) and 1(9%) from relapse, 5 (26.3%) pts had mixed chimerism
(MC) with .90%\99% DC of who 3 (60%) stayed in CR, 2 (40%)
relapsed with one death and 3 (15.8%) pts had MC with\90% DC
of who 2 had persistent and one relapsed disease. Overall, 13
(52.6%) pts stayed in CR, 4 relapsed irrespective of D100 chimeric
status and 9 (37.5%) died from progressive disease or TRT.
Conclusion:We conclude that reduced intensity transplantation,
with non-targeted dose Busulfan and Fludarabine is well tolerated,
with favorable engraftment kinetics and low relapse rates, compara-
ble to historic controls. Therefore, targeted dose Busulfan may not
affect the outcome of transplant.
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MEDICAL MANAGEMENT OF PNEUMATOSIS INTESTINALIS IN PATIENTS
UNDERGOING ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION
Ahluwalia, M.S.1, Anne, N.2, Smiley, S.L.1, Battiwalla, M.1,
Schiff, M.D.1, Loud, P.A.3, Hahn, T.1, Bullard Dunn, K.M.2,
McCarthy, P.L.1 1Roswell Park Cancer Institute, Buffalo, NY; 2Roswell
Park Cancer Institute, Buffalo, NY; 3Roswell Park Cancer Institute, Buf-
falo, NY
Pneumatosis intestinalis (PI) occurs when gastrointestinal (GI)
wall disruption, increased GI wall permeability or necrosis leads to
GI wall infiltration by gas. It is associated with a spectrum of causal
factors including GI disease in allogeneic Blood and Marrow Trans-
plant (alloBMT) patients (pts). Anaerobic bacteria likely produce gas
which accumulates in the GI wall. Traditionally, PI has been man-
aged with surgical exploration with high morbidity and mortality.
We describe our institutional experience managing alloBMT pts
with PI. From 01/98 to 05/08, 320 pts underwent alloBMT of
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abdominal pain, abdominal distention, cough and respiratory
distress. Diagnosis was established by CT scan (n 5 7), plain film
(n5 2) or colonoscopy (n5 1). Nine of 10 pts had ongoing GI graft
versus host disease (GvHD) at diagnosis or a recent history of treat-
ment for GI GvHD. Prior to 04/02, 2 pts underwent subtotal colec-
tomy with ileostomy (n5 1) and sigmoid colectomy with colostomy
(n 5 1). One pt was managed with bowel rest and total parental
nutrition (TPN) only. These 3 pts died 0.4, 1.1, and 3.9 years after
PI diagnosis due to GI GvHD (n5 2) and surgical complications af-
ter colostomy revision (n 5 1). Seven PI pts diagnosed after 09/06
were treated with GI rest, TPN and oral antibiotics (rifaximin,
augmentin and metronidazole) to decrease anaerobic bowel flora.
Median duration of antibiotic use was 47 days (range:26–1361,
one pt was still on antibiotics as of last follow up on 10/3/08), median
duration of TPN was 41 days (range:25–64) and median duration of
GI rest was 23 days (range:3–34). On this regimen, all 7 patients had
resolution of PI at a median time of 36 days (range:10–70). Of the 7
pts, 5 died due to GI GvHD (n5 3), relapsed disease (n5 1) or pre-
existing diverticulitis (n 5 1) at 0.92, 0.46, 0.07, 0.15, and 1.3 years
after PI diagnosis. PI pts treated with GI rest, TPN and oral antibi-
otics may have resolution of PI. In most cases it is a non-critical find-
ing that does not represent true GI tract ischemia and/or GI tract
perforation. Non-surgical management of PI with therapy directed
against anaerobic bacteria may result in complete resolution.313
USE OF PALIFERMIN IN ALLOGENEIC STEM CELL TRANSPLANTATION
(SCT) FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Anderson, J.E.1, Gulbis, A.M.1, Cool, R.M.1, Westmoreland, M.D.1, de
Lima, M.2, Giralt, S.2, Hosing, C.2, Popat, U.2, Qazilbash, M.H.2,
Shpall, E.2, Khouri, I.F.2, Champlin, R.2, Kebriaei, P.2 1University of
Texas M.D. Anderson Cancer Center, Houston, TX; 2University of Texas
M.D. Anderson Cancer Center, Houston, TX
Background: Palifermin is a recombinant keratinocyte growth
factor (KGF) approved to decrease the incidence and severity of
mucositis in stem cell transplantation. Furthermore, effects on the
KGF receptor may modulate and minimize acute GVHD. Studies
utilizing palifermin have been conducted in autologous SCT; how-
ever, literature regarding use in allogeneic SCT is minimal.
Methods:We evaluated time to engraftment, incidence/duration
of mucositis, and incidence of acute GVHD in 22 ALL patients (15
M/7 F) treated from 2004 to 2008 with 12GyTBI, etoposide 60mg/
kg, and unmanipulated cells. Seven patients received weekly rituxi-
mab at 375 mg/m2 x 4 doses as part of a study. GVHD prophylaxis
consisted of mini-dose methotrexate and tacrolimus. Anti-
thymocyte-globulin was added to matched unrelated patients.
Patients also received 3 daily doses of palifermin 60 mcg/kg preced-
ing initiation of chemotherapy, and following stem cell infusion.
Outcomes were compared to a historical control group of 19 ALL
patients (12 M/7 F) treated with a TBI-based preparative regimen
who did not receive palifermin.
Results: The median age in the palifermin arm was 36.5 years
(19–51) versus 34 years (16–52) in the historical arm. Donor type
was matched related or matched unrelated in 12 and 10 patients,
respectively, in the palifermin arm versus 11 and 8 patients, respec-
tively, in the historical arm. All patients in palifermin and historical
control groups developed mucositis. The median duration of muco-
sitis was 13 days (3–28) in the historical arm and 14 days (3–27) in the
palifermin arm. Patient-controlled analgesia was used in 14 patients
for a median of 13.5 days in the historical arm versus 17 patients for
a median of 13 days in the palifermin arm. Median time to ANC $
0.5  109/L was 15 days (12–26) for the palifermin arm versus 14
days (12–26) for the historical arm; median time to platelet count
$ 20  109/L was 15 days (6–30) for the palifermin arm and 13
days (5–37) for the historical arm. The incidence of grades II-IV
and III-IV acute GVHD were 18% (n5 4) and 5% (n5 1), respec-
tively, in the palifermin arm versus 32% (n 5 6) and 11% (n 5 2),
respectively, in the historical arm.
Conclusions: Palifermin use for allogeneic SCT is feasible with
no impact on engraftment, and possibly reduction in acute
GVHD. However, we failed to detect reduction of mucositis with
palifermin use. Our observations are limited by the retrospective na-
ture of the comparisons and small patient numbers.314
FEASIBILITY OF ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION (ALLO-SCT) FOLLOWING REDUCED INTENSITY CONDITION-
ING (RIC) IN HIV1 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Hamadani, M., Baiocchi, R., Lin, T., Blum, K.A., Ezzone, S.,
Benson DM Jr., Jr., Devine, S.M. Arthur G. James Comprehensive Can-
cer Center, the Ohio State University, Columbus, OH
The role of RIC Allo-SCT in HIV1 patients with hematological
malignancies remains to be defined. We employed a uniform strat-
egy of RIC consisting of fludarabine (30 mg/m2/day, days 27 to
23), busulfan (0.8 mg/kg/dose IV 8 doses) with (n5 2) or without
(n5 1) (6mg/kg) rabbit ATG in three HIV1 patients with hemato-
logical malignancies. Median patient age was 51 yrs (range 39–55
yrs). One patient each had AML, Burkitt’s lymphoma and plasma-
blastic lymphoma. All patients were in CR2 at the time of transplan-
tation. Median pre-transplant (preT) CD4 count was 339cells/uL
(range 189–457cells/uL). 2 patients had undetectable HIV viral
load preT, while it was 814copies/ml in the third patient. All patients
had HCI-comorbidity index of$3. Donors included sibling (n5 1)
or unrelated volunteers (n5 2). GVHDprophylaxis consisted of mi-
cro-dose methotrexate and tacrolimus. HAART was not interrupted
during or after transplantation. All patients engrafted promptly
following transplantation. Only one patient developed transient
stage III cutaneous acute GVHD.While one patient each developed
extensive and limited chronic GVHD. At a median follow-up of 375
days (range 71–526 days) all patients are alive, with no evidence of
disease relapse. Post-transplant HIV viral load remains undetectable
in 2 patients. In the third patient mildly elevated HIV viral load
(2000copies/ml) on day 1252, promptly became undetectable with
second line HAART. Similarly the CD4 count remained
.200cell/uL at all measurements post-transplantation. Chimerism
analysis showed 100% donor CD331 chimerism at all time points
(days 30, 90, 180 and 1365) and median donor CD31 chimerism
of 90%, 84%, and 100% at days130, 1180 and1365. One patient
developed CMV reactivation which responded to preemptive antivi-
ral therapy.No patients developed anyHIV related opportunistic in-
fections. This case series provides critical preliminary evidence that
RIC Allo-SCT with concurrent uninterrupted HAART is safe and
feasible in HIV1 patients with malignant hematological disorders.315
A SINGLE APHERESIS PROCEDURE IN THE DONOR MAY BE ENOUGH TO
COMPLETE AN ALLOGRAFT USING THE ‘‘MEXICAN METHOD’’ OF NON-
ABLATIVE ALLOGRAFTING
Ruiz-Delgado, G.J.1,2, Gutierez-Riverollu, K.I.1, Gutirrez-
Aguirre, C.H.3, Gomez-Almaguer, D.3, Eyzaguirre-Zapata, R.1,
Priesca-Marin, M.4, Marin-Lopez, A.4, Ruiz-Arguelles, G.J.1,2 1Centro
de Hematologia y Medicina Interna de Puebla, Puebla, PUE, Mexico;
2Laboratorios Clınicos de Puebla, Puebla, PUE, Mexico; 3Hospital Uni-
versitario de Nuevo Leon, Monterrey, NL, Mexico; 4Servicios Integrales
de Medicina Transfusional y Hemaferesis de Puebla, Puebla, PUE, Mexico
We have analyzed the salient apheresis features of a group of 175
allogeneic peripheral blood stemcell transplants conducted in two in-
stitutions in a seven-year period.The graftswere conducted using the
‘‘Mexican’’ non-myeloablative conditioning regimen employing oral
busulphan, iv cyclophosphamide and iv fludarabine. In all instances,
the apheresis machine employed was the Baxter CS3000 Plus and
donors were mobilized with filgrastim. The apheresis procedures
were performed on days24,23, and – 2, the endpoint of collection
being 5 000 ml of blood / m2 in each procedure. Three apheresis ses-
sions were planned but the number was adjusted according to the cell
yield.The final number of allograftedCD34 cells ranged between 0.5
and 25.4 106/Kg of the recipient (median 5.2  106/Kg). One to 3
apheresis procedures were needed to accomplish a product contain-
ing above 0.5 106/Kg of the recipientCD34 cells, themedian being
2 procedures; in 72 cases (41%) a single apheresis procedure was
enough to obtain the target number of CD34 cells. The apheresis
products volumes ranged between 50 and 600ml (median 400). Since
the median cost of each apheresis procedure is 900 USD, the cost of
two apheresis procedures was spared in 72 procedures, whereas the
cost of one was spared in 65, thus making an approximate total
amount of 188 100 USD saved. It is concluded that allogeneic trans-
plants can be completed using a single apheresis session and that con-
siderable economic consequences can be derived from this practice.
